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27 
28       Non-viral  delivery  of  single  genes  combined  with  biomaterial  scaffolds  is  increasingly  showing 
29 
30       potential   in   tissue   engineering.   In   this   study,   we   developed   a   bioactive,   collagen   nano- 
31 
32       hydroxyapatite (coll-nHA) scaffold as a dual gene delivery platform in vitro and in vivo. Firstly, the 
33 
34       
ability of nHA particles, developed in-house, and polyethylenimine (PEI) to act as non-viral vectors 
35       for  delivery  of  bone  morphogenetic  protein  2  (pBMP2)  and  vascular  endothelial  growth  factor 
36 
37       (pVEGF), pro-osteogenic and pro-angiogenic genes respectively, was determined in mesenchymal 
38 
39       stem cells (MSCs). nHA and PEI were then combined with the genes in various combinations with 
40 
41       coll-nHA scaffolds to produce a scaffold highly conducive to the production of vascularised bone. 
42       
These  dual  combinatorial  pVEGF/pBMP2  gene-activated  scaffolds  demonstrated  superior  MSC- 
44       mediated osteogenesis in vitro and increased vascularisation and bone repair by host cells in vivo. 
45 
46       Ultimately, the use of nHA to deliver both pVEGF and pBMP2 markedly accelerated bone healing 
47 
48       with a 36-fold increase in bone formation in the nHA dual scaffold versus the empty defect as early 
49 
50       as 4 weeks post-implantation underlining its immense potential in bone regeneration. 
51 
52 
53       Although bone can regenerate following fracture, large bone defects have limited capacity for repair 
54 
55       and as such require alternative strategies. Tissue-engineered scaffolds are promising alternatives to 
56 
57       bone grafts as they can provide both a functional three-dimensional template that houses cells and, 
58       
in addition, can be designed to facilitate the controlled release of recombinant proteins or genes to 
60       enhance healing. The use of proteins is associated with limitations including high cost, bolus release
60 
61 
62 
63 
64 
65 
 
19 
43 
50 
of  protein,  short  half-life,  and  the  large  doses  needed  to  achieve  a  therapeutic  effect.  Gene- 
1 
2       activated scaffolds are a new avenue of research and consist of biomaterial scaffolds functionalised 
3       
to act as depots for gene delivery while simultaneously offering structural support and a matrix for 
4 
5       new  tissue  deposition.  A  gene-activated  scaffold  can  therefore  induce  the  body’s  own  cells  to 
6 
7       steadily produce specific proteins providing a much more efficient alternative. 
8 
9 
10       The dual delivery of therapeutic proteins or genes may have increased regenerative potential over 
11       
the delivery of single proteins or genes [1, 2]  and although dual delivery scaffolds have previously 
12 
13       been developed, they typically deliver proteins [3-5].   The next generation gene-activated scaffold 
14 
15       might therefore include multiple genes to promote synergistic cell-mediated protein production. In 
16 
17       bone repair, neo-vascularisation of the damaged bone is critical to the healing outcome. Therefore a 
18       
dual  scaffold  containing  an  angiogenic  gene  to  promote  vascularisation  combined  with  an 
20       osteogenic  gene  may  enhance  bone  repair.  Few  in  vitro  gene  delivery  systems  providing  co- 
21 
22       expression of therapeutic genes have been demonstrated using multi-gene combinations [6-8] and to 
23 
24       our knowledge, no bone-targeted scaffold containing different non-viral vectors carrying alternate 
25 
26       therapeutic  genes  has  been  reported.  This  study  thus  focused  on  the  development  of  a 
27       
combinatorial dual gene-activated scaffold to deliver two different genes - pVEGF and pBMP2. BMP2 
28 
29       is well known for its therapeutic capacity for bone repair  [9-11]   while VEGF is typically used for 
30 
31       vascularisation. A small number of in vitro and in vivo studies have reported the synergistic effects of 
32 
33       dual VEGF and BMP2 protein delivery relative to singular systems 
[3, 4, 12]. 
34 
35       Non-viral vectors were utilised in the development of these scaffolds to overcome safety problems 
36 
37       associated with viral vectors such as insertional mutagenesis [13] and adverse immune responses [14]. 
38 
39       Recently  within  our  laboratory,  polyethyleneimine  (PEI)  has  been  optimised  as  a  vector  within 
40 
41       collagen-based   scaffolds   demonstrating   efficacy   with   a   high   transfection   efficiency   and 
42       
uncompromised cell viability [15,  16]. In addition, in-house synthesised nano-hydroxyapatite (nHA), 
44       which was initially used to improve the mechanical properties and osteogenic potential of the 
45 
46       scaffolds,  [17]   was  also  recently  adapted  in  our  lab as  a  vector  for  MSC transfection  [18]   where 
47 
48       significantly elevated levels of MSC-mediated mineralisation were observed in nHA-pBMP2 coll-nHA 
49       
scaffolds [18]. 
51 
52       The hypothesis of this study is that a multi-faceted approach of a scaffold optimised for bone repair 
53 
54       containing osteogenic and angiogenic genes delivered with individual non-viral vectors tailored for 
55 
56       transfection of MSCs would have immense potential for bone repair. Therefore, the overall goal of 
57 
58       this  study  was  initially  to  establish  the  optimal  vector  for  the  delivery  of  pVEGF  and  pBMP2 
59
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individually before incorporating both in a combinatorial dual scaffold to promote MSC-mediated 
1 
2       osteogenesis in vitro and increased host-mediated vascularisation and bone repair in vivo. 
3 
4       Firstly, the respective transfection efficiencies of the PEI and nHA vectors were determined using the 
5 
6       reporter  gene  plasmid  Green  Fluorescent  Protein  (pGFP)  and  compared  to  nucleofection  as  a 
7 
8       positive control (Fig 1a). Nucleofection led to the highest levels of transfection with a gene transfer 
9 
10       efficiency of 80.1 ± 9.3% and PEI yielded higher levels of transfection (30.4 ± 8.4%) than nHA (11.5± 
11       
1.3%). 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
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35 
36       
Figure 1. nHA and PEI result in enhanced delivery of functional BMP2 and VEGF to MSCs. a, Nucleofection promotes the 
37 
38       most effective transfection followed by PEI. b, BMP2 production was highest following PEI transfection. c, Similarly, the 
39       highest VEGF production occurred following PEI transfection. d, Increased osteoblast differentiation was observed when 
40 
41       treated with media taken from PEI-pBMP2 and nHA-pBMP2 transfected cells in comparison to the addition of recombinant 
42       BMP2 protein. e, Enhanced calcium/DNA content was obtained in the nHA-pBMP2 transfected group compared to all other 
43 
44       groups analysed. Enhanced proliferation of endothelial cells was observed when treated with media taken from PEI-pVEGF 
45       or nHA-pVEGF transfections.  *p ≤0.05 
46 
47 
48       
MSCs were then transfected/nucleofected with pBMP2 to analyse the ability of each vector to elicit 
49 
50       functional BMP2 production. All vectors successfully led to the production of BMP2 protein (Fig. 1b) 
51 
52       but PEI-pBMP2 transfection induced remarkably higher levels of BMP2 production. Although PEI- 
53 
54       pGFP  expression  was  almost  3-fold  lower  than  nucleofection,  PEI-pBMP2  expression  exceeded 
55 
56       
nucleofection.  Similarly,  MSCs  were  transfected/nucleofected  with  pVEGF  where  all  vectors 
57       increased VEGF protein expression but cells transfected with PEI-pVEGF again induced the highest 
58 
59       levels of VEGF expression (Fig. 1c). In order to verify the bioactivity of this BMP2, media from the
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11 
27 
35 
51 
transfected MSCs was added to pre-osteoblasts and calcium deposition was measured (Fig. 1d). 
1 
2       Interestingly, the nHA-pBMP2 group had significantly increased calcium/DNA deposition relative to 
3       
all other groups (Fig. 1d). Moreover, the addition of both nHA-pBMP2 media and PEI-pBMP2 media 
4 
5       from transfected cells promoted significantly higher calcium deposition compared to the addition of 
6 
7       50ng/ml of recombinant BMP2 protein (recommended dose). This indicates that the BMP2 levels 
8 
9       produced  using  non-viral  gene  therapy  were  more  effective  than  the  direct  addition  of  BMP2 
10       
recombinant protein – the current clinical standard. Osteogenic assays performed on the transfected 
12       MSCs showed that nHA-pBMP2 transfected MSCs produced statistically higher levels of calcium/DNA 
13 
14       than all other groups indicating that nHA-pBMP2 provides levels of BMP2 conducive to enhanced 
15 
16       osteogenesis (Fig. 1e).  Of particular note is that the very high levels of BMP2 expression seen with 
17 
18       PEI-pBMP2 transfected cells did not translate into higher levels of calcium suggesting high levels of 
19       BMP2  expression  may  not  directly  translate  to  increased  osteogenesis  and  thus  therapeutic 
20 
21       potential. As endothelial cells proliferate in response to the addition of VEGF, VEGF functionality was 
22 
23       analysed by adding media from pVEGF-transfected MSCs to endothelial cells (HUVECs; Fig. 1f). At 
24 
25       day 3, the levels of DNA measured in the PEI-pVEGF group was significantly higher than the nHA- 
26       
pVEGF group and endothelial cells alone. However, at day 7 both vectors increased endothelial cell 
28       proliferation relative to the cells alone control indicating that both vectors are suitable for pVEGF 
29 
30       delivery and therefore for enhancing angiogenesis while suggesting that PEI is superior. 
31 
32 
33       Having characterised protein expression and osteogenesis in monolayer culture, the pDNA-vector 
34       
complexes were applied to scaffolds in various combinations as outlined in Fig. 2a, i.e. the PEI dual 
36       (PEI-pVEGF/PEI-pBMP2), nHA dual (nHA-pVEGF/nHA-pBMP2) and a mix dual gene-activated scaffold 
37 
38       (composed  of  PEI-pVEGF  and  nHA-pBMP2  based  on  the  optimal  gene  vectors  derived  from 
39 
40       monolayer in vitro experiments), to assess their potential. All three dual scaffolds were shown to 
41 
42       augment MSC-mediated calcium deposition and mineralisation in vitro after only 14 days. MicroCT 
43       
images and alizarin red staining (Fig. 2b) showed marked increases in calcium production in the nHA 
44 
45       dual and particularly the mix dual scaffold. Calcium quantification confirmed that both the mix dual 
46 
47       scaffold and nHA dual scaffold induced the highest levels calcium deposition (Fig. 2c). The lower 
48 
49       levels of mineralisation observed in the PEI dual scaffold despite the high levels of VEGF and BMP2 
50       
production was an unanticipated finding indicating that excessive amounts of protein production 
52       may actually deter osteogenesis. Ultimately, the enhanced osteogenesis observed in both the nHA 
53 
54       and mix dual scaffold was very encouraging. Subsequently, gene-activated scaffolds containing pGFP 
55 
56       complexed with either PEI or nHA were implanted in a rat cranial defect where the presence of GFP 
57 
58       expressing cells confirmed the capability of these scaffolds to recruit and transfect host cells in vivo 
59       (Fig. 2d).
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19 
20 
21 
22 
23       Figure 2. Development of functional dual gene-activated scaffolds for in vitro and in vivo gene delivery. a, Schematic of 
24 
25       dual pVEGF-pBMP2 scaffolds. b, Reconstructed microCT images and alizarin red staining of dual scaffolds. c, Quantification 
26       showed that the mix dual and nHA dual scaffold enhanced osteogenesis relative to the gene-free and the PEI dual scaffold. 
27 
28       d, GFP-expressing cells were observed in pGFP scaffolds implanted in a rat cranial defect for 1 week. *p ≤0.05 
29 
30 
31       Following  in  vitro  confirmation  of  their  enhanced  osteogenic  potential  and  confirmation  of 
32 
33       successful in vivo transfection of host cells, the ability of the therapeutic dual scaffolds to promote 
34 
35       vascularisation and bone repair was assessed in a rat critical-sized cranial defect model. Qualitative 
36       microCT  and  histological  analysis  revealed  that  all  combinatorial  dual  scaffolds  contributed  to 
37 
38       enhanced tissue healing as noted in Fig. 3. However, the nHA dual scaffold displayed the most 
39 
40       advanced healing profile with good cell infiltration, large areas of deeply stained bone nucleation 
41 
42       sites, and good integration at the interface between the scaffold and the defect edge (Fig 3a). 
43       
Quantitative   microCT   analysis   (Fig.   3b)   showed   that   it   produced   higher   percentage   bone 
45       volume/tissue  volume  (BV/TV)  than  all  other  groups.  The  mix  dual  scaffold  also  induced  a 
46 
47       significantly  pronounced  healing  response  and  while  the  PEI  dual  scaffold  did  not  statistically 
48 
49       augment bone volume in the defect site relative to the gene-free scaffold, it did elicit an enhanced 
50 
51       response when compared to the empty defect control. Histomorphometrical analysis corroborated 
52       these results (Fig. 3c). Measurement of new bone formation revealed significantly higher levels of 
53 
54       new bone in the nHA dual scaffold, the mix dual scaffold contained the next highest levels, the PEI 
55 
56       dual scaffold induced more bone than the gene-free scaffold and finally, the gene-free scaffold 
57 
58       induced more than the empty defect. In order to further understand the mechanism for accelerated 
59       
bone  regeneration,  vessel  formation was  analysed  (Fig.  3d-e).  The  mix  dual  scaffold  contained
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significantly more vessels than the empty defect and interestingly, the nHA dual scaffold had more 
1 
2       vessels than any other group. It is likely therefore that the higher levels of VEGF produced by cells 
3       
transfected in the mix dual scaffold and the nHA dual scaffold are responsible for this increased 
4 
5       vessel formation. 
6 
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36 
37 
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39 
40 
41       Figure 3. Enhanced bone repair and vessel formation in dual gene-activated scaffolds. a, Qualitative microCT analysis and 
42 
43       
macroscopic and high magnification images of H & E stained sections of each defect. All dual scaffolds displayed some
 
44       degree of healing but the nHA dual scaffold promoted the highest levels of bone formation as demonstrated when b, 
45       
microCT  results  were  quantified.  c,  Quantitative  histomorphometric  analysis  detailing  the  mean  total  area  of  bone 
46 
47       nucleation sites corroborated these results. d, Representative image of CD31 positive vessels in defect. e, Quantification of 
48       
vessel number revealed that the nHA dual scaffold had more vessels than any other group. * Blue arrows represent fibrotic 
49 
50       regions, green arrows represent acellular regions, yellow arrows represent areas of new bone formation/bone nucleation 
51       sites/good integration with surrounding bone, white arrows represent CD31 stained vessels. *p ≤0.05 
52 
53 
54       This  study  demonstrates  accelerated  bone  regeneration  through  the  combination  of  coll-nHA 
55 
56       scaffold engineered specifically for bone repair with the sustained localised delivery of both an 
57 
58       angiogenic and an osteogenic gene and represents a promising new concept in tissue engineering. 
59 
60       The importance of vector choice was also shown to be essential.  In gene therapy, high transfection
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11 
efficiencies  are  sought  after  but  interestingly,  even  though  nHA  resulted  in  less  cell-mediated 
1 
2       protein  production,  the  nHA  dual  scaffold  ultimately  demonstrated  the  greatest  potential  for 
3       
enhancing in vivo bone formation. Furthermore, non-viral vectors are generally cited as relatively 
4 
5       inefficient to their viral counterparts [19] meaning they are often disregarded in favour of viral vectors 
6 
7       
[20]. Herein, we have shown the therapeutic efficacy of using non-viral vectors in a 3D scaffold both in 
8 
9       vitro and within a critical-size defect in vivo indicating that they should not be overlooked in the 
10       
derivation of new therapeutics in the field. From a therapeutic perspective, all combinatorial dual 
12       gene-activated scaffolds were successful in increasing bone regeneration but markedly accelerated 
13 
14       bone healing was observed in the nHA dual gene-activated scaffold. After only 4 weeks, a very early 
15 
16       timepoint in the bone healing timeframe, rats treated with the nHA dual scaffold displayed complete 
17 
18       bridging of the defect. Collectively, this study has underlined the potential of a series of non-viral 
19       gene-activated scaffolds in bone regeneration. Conclusively, the nHA dual scaffold emerged as a 
20 
21       scaffold with immense potential in non-viral orthopaedic gene therapy. 
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Experimental Section 
1 
2       
Refer to Supplementary Methods for more detailed descriptions. 
4 
5 
6       Cell culture 
7 
8       MSCs, HUVECs, MC3T3-E1s were cultured using standard cell culture techniques as described in 
9 
10       Supplementary Methods. 
11 
12 
13       Plasmid propagation & Cell transfection 
14 
15       Plasmid amplifications were carried out by transforming One Shot® TOP10 Chemically Competent E. 
16 
17       coli bacterial cells (Biosciences) according to the manufacturer’s protocol and isolating pDNA using a 
18       
Plasmid Maxi Kit (Qiagen). PEI [15] and nHA transfections [18] were carried out as detailed previously. 
20       Nucleofection was carried out as per manufacturer’s instructions (Amaxa). 
21 
22 
23 
24       Enzyme-linked Immunosorbent Assay (ELISA) for BMP2 and VEGF quantification post transfection 
25 
26       The cell culture supernatant was collected and analysed by ELISA according to the manufacturer’s 
27       
instructions. 
28 
29 
30 
31       Gene-activated scaffold fabrication 
32 
33       The  coll-nHA  scaffold  was  fabricated  and  crosslinked  as  previously  described  
[18].  PEI-pDNA 
34       
complexes and nHA-pDNA nanoparticles were soak-loaded onto the scaffolds to form gene-activated 
36       scaffolds [15, 18]. 
37 
38 
39 
40       Osteogenesis assays 
41 
42       Cells/scaffolds were cultured in osteogenic media consisting of DMEM supplemented with 10% FBS, 
43       
1%  penicillin/streptomycin,  10mM  β-glycerophosphate  (Sigma-Aldrich),  50µm  ascorbic  acid  2- 
44 
45       phosphate    (Sigma-Aldrich)    and    100nM    dexamethasone    (Sigma-Aldrich).    Post-transfection, 
46 
47       cells/scaffolds were assayed at 14 days for calcium deposition as a measure of osteogenesis using a 
48 
49       Stanbio calcium assay (Calcium CPC Liquicolour, Stanbio Inc.) and DNA quantification was performed 
50       
using a Quant-iT™ PicoGreen® dsDNA kit (Invitrogen). Scaffolds were qualitatively analysed in vitro 
52       using microcomputed tomography (Medical 40 MicroCT system, Scanco). Alizarin red staining was 
53 
54       also performed on 7µm sections of the scaffolds.
54 
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43 
Bioactivity analysis of BMP2 and VEGF produced by transfected MSCs 
1 
2       MSCs were transfected with PEI/nHA-pBMP2 and cultured in pre-osteoblast (MC3T3-E1) growth 
3       
media.  The  conditioned  media  i.e.  supernatant  from  transfected  MSCs  was  applied  to  pre- 
4 
5       osteoblasts in a 1:1 ratio with osteogenic media and an osteogenic assay was performed. Similarly, 
6 
7       rMSCs were transfected with PEI/nHA-pVEGF and cultured in endothelial cell (HUVEC) growth media. 
8 
9       The  media  from  transfected  rMSCs  was  applied  to  endothelial  cells  in  a  1:1  ratio  CM:fresh 
10       
endothelial cell media. DNA quantification was performed as a measure of proliferation. 
12 
13 
14       Surgical procedure 
15 
16       Ethical approval was given by the Research Ethics Committee of RCSI (REC Approval No. 662) and an 
17 
18       animal license by the Department of Health of the Irish Government (Ref. B100/4416). A 7mm 
19       
circular transosseous defect was created in the rat’s cranium and the scaffolds were immediately 
20 
21       inserted. Animals were sacrificed 1 or 4 weeks post-surgery by CO2  asphyxiation. The defect area 
22 
23       was resected for analysis. 
24 
25 
26       
Qualitative and quantitative analysis of bone healing using microCT 
28       Scans and reconstructions were performed and bone repair was expressed as a percentage of bone 
29 
30       volume over total volume (% BV/TV) within the defect area. 
31 
32 
33 
34       Histomorphometrical analysis of bone healing 
35       
Specimens were decalcified in 10% formic acid, bisected and embedded in paraffin wax blocks. 7µm 
36 
37       sections were then cut, de-paraffinised, rehydrated through decreasing grades of alcohol, stained 
38 
39       with haemotoxylin and eosin, dehydrated with increasing grades of alcohol, mounted and imaged. 
40 
41       Areas of new bone formation were identified by deep pink staining and quantified by measuring 
42       
their area in each section and calculating the mean total area per group. 
44 
45 
46       Quantification of vessel formation 
47 
48       Histological sections were de-paraffinised, rehydrated, incubated in a primary mouse anti-rat CD31 
49 
50       antibody tagged with TRIT-C (BD) and mounted. 5 random sections were acquired for each sample, 
51       
the amount of vessels in each section was collated and vessel quantification was presented as the 
52 
53       mean value for the sum of these 5 sections.
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11 
Results  are  expressed  as  the  mean  ±  standard  deviation.  Statistical  significance  was  generally 
1 
2       assessed using One-way ANOVA with post hoc Holm-Sidak tests. Two-way ANOVA followed by post 
3       
hoc Holm-Sidak tests were carried out in Figures 1b, 1c, & 1f. The sample size was n=3 for in vitro 
4 
5       studies and n=8 for in vivo studies where p≤0.05 values were considered statistically significant. 
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